Aprepitant vs. Gabapentin — Competitive Intelligence Brief

Aprepitant vs. Gabapentin (Aprepitant vs. Gabapentin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NK1 receptor antagonist. Area: Oncology.

phase 2 NK1 receptor antagonist NK1 receptor Oncology Small molecule

Target snapshot

Aprepitant vs. Gabapentin (Aprepitant vs. Gabapentin) — New Mexico Cancer Research Alliance. Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist, which blocks the action of substance P, a natural substance in the body that causes nausea and vomiting.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aprepitant vs. Gabapentin TARGET	Aprepitant vs. Gabapentin	New Mexico Cancer Research Alliance	phase 2	NK1 receptor antagonist	NK1 receptor
EMEND	EMEND	Merck Sharp & Dohme LLC	marketed	Neurokinin-1 (NK1) receptor antagonist	NK1 receptor (neurokinin-1 receptor)
Dexamethasone, Ondansetron, Aprepitant	Dexamethasone, Ondansetron, Aprepitant	Ottawa Hospital Research Institute	marketed	Antiemetic combination (corticosteroid + 5-HT3 antagonist + NK1 antagonist)	Glucocorticoid receptor, 5-HT3 receptor, NK1 receptor
Aprepitant plus Ondansetron	Aprepitant plus Ondansetron	University of Pittsburgh	marketed	NK1 receptor antagonist + 5-HT3 receptor antagonist combination	NK1 receptor (aprepitant); 5-HT3 receptor (ondansetron)
Akynzeo solution	Akynzeo solution	Helsinn Healthcare SA	marketed	NK1 receptor antagonist / 5-HT3 receptor antagonist combination	NK1 receptor (netupitant component); 5-HT3 receptor (palonosetron component)
Fosaprepitant for Injection	Fosaprepitant for Injection	Montefiore Medical Center	marketed	NK1 receptor antagonist	NK1 receptor (neurokinin-1 receptor)
fosnetupitant/ palonosetron	fosnetupitant/ palonosetron	Helsinn Healthcare SA	marketed	NK1 receptor antagonist / 5-HT3 receptor antagonist combination	NK1 receptor (substance P receptor) / 5-HT3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NK1 receptor antagonist class)

1. Merck Sharp & Dohme LLC · 4 drugs in this class
2. GlaxoSmithKline · 3 drugs in this class
3. Organon and Co · 3 drugs in this class
4. CCTU · 2 drugs in this class
5. Acacia Pharma Ltd · 2 drugs in this class
6. Sanofi · 1 drug in this class
7. Santen SAS · 1 drug in this class
8. CR-CSSS Champlain-Charles-Le Moyne · 1 drug in this class
9. Montefiore Medical Center · 1 drug in this class
10. New Mexico Cancer Research Alliance · 1 drug in this class